Abstract:Chronic liver injury is accompanied by a dysbalanced scarring process, termed fibrosis. This process is mainly driven by chronic inflammation and an altered activity of a multitude of different chemokines and cytokines, resulting in the infiltration by immune cells (especially macrophages) and increase of matrix-expressing cell types. These processes might lead to cirrhosis representing the end-stage of fibrosis. Recent clinical studies comprising patients successfully treated for viral hepatitis showed that liver fibrogenesis and even cirrhosis may be reverted. The hepatic capacity to remodel scar tissue and to revert into a normal liver follows specific mechanistic principles that include the termination of chronic tissue damage, shifting the cellular bias from inflammation to resolution, initiation of myofibroblast apoptosis or senescence and, finally, fibrinolysis of excess scar tissue. The plurality of molecular and cellular triggers involved in initiation, progression and resolution of hepatic fibrogenesis offers an infinite number of therapeutic possibilities. For instance, inflammatory macrophages can be targeted via inhibition of chemokine CCL2 or its receptor CCR2 (e.g., by cenicriviroc) as well as by transfer of restorative macrophage subsets. Another target is galectin-3 that acts at various stages along the continuum from acute to chronic inflammation. Profibrogenic cytokines (e.g., transforming growth factor-β), matricellular proteins (e.g., CCN1/CYR61) or signaling pathways involved in fibrogenesis offer further possible targets. Other options are the application of therapeutic antibodies directed against components involved in biogenesis or remodeling of connective tissue such as lysyl oxidase-like-2 or synthetic bile acids like obeticholic acid that activate the farnesoid X receptor and was antifibrotic in a phase 2 study (FLINT trial). Factors affecting the gut barrier function or the intestinal microbiome further expanded the repertoire of drug targets. In this review, we discuss novel concepts in resolution of hepatic fibrosis and focus on drug targets that might be suitable to trigger resolution of fibrosis.

Fibrosis: from mechanisms to medicines

Targeting Fibrosis: From Molecular Mechanisms to Advanced Therapies

Mechanisms of organ fibrosis: Emerging concepts and implications for novel treatment strategies

Liver fibrosis: Pathophysiology and clinical implications

Therapeutic targets of fibrosis: Translational advances and current challenges

Pulmonary fibrosis: Emerging diagnostic and therapeutic strategies

Cellular and Molecular Mechanism of Liver Fibrosis: A Critical Insight

Organ and tissue fibrosis: Molecular signals, cellular mechanisms and translational implications

Targeting Fibrosis: Mechanisms and Clinical Trials

Liver Fibrosis: Mechanistic Concepts and Therapeutic Perspectives

Epigenetic Modifications in Fibrotic Diseases: Implications for Pathogenesis and Pharmacological Targets

Clinical Advancements in the Targeted Therapies against Liver Fibrosis

Epigenetic modifications in fibrotic diseases: implications for pathogenesis and pharmacological targets.

Integrating mechanisms of pulmonary fibrosis

The Processes and Mechanisms of Cardiac and Pulmonary Fibrosis

Liver Fibrosis: From Pathogenesis to Novel Therapies

Towards better definition, quantification and treatment of fibrosis in heart failure. A scientific roadmap by the Committee of Translational Research of the Heart Failure Association (HFA) of the European Society of Cardiology

Fibrometabolism-An emerging therapeutic frontier in pulmonary fibrosis

Targeting fibrosis, mechanisms and cilinical trials

Epigenetics and Fibrosis